AVALO THERAPEUTICS, INC. Impairment of Intangible Assets, Finite-lived
AVALO THERAPEUTICS, INC. (AVTX) reported Impairment of Intangible Assets, Finite-lived of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2020-03-11
- AVALO THERAPEUTICS, INC. impairment of intangible assets, finite-lived for the quarter ending 2018-09-30 was $1.90M.
- AVALO THERAPEUTICS, INC. impairment of intangible assets, finite-lived for the quarter ending 2018-06-30 was $1.90M.
- AVALO THERAPEUTICS, INC. impairment of intangible assets, finite-lived for fiscal 2019 was $0.00.
- AVALO THERAPEUTICS, INC. impairment of intangible assets, finite-lived for fiscal 2017 was $0.00.
| Period end | Impairment of Intangible Assets, Finite-lived 3 month | Impairment of Intangible Assets, Finite-lived 6 month | Impairment of Intangible Assets, Finite-lived 12 month |
|---|---|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-03-11 | ||
| 2018-09-30 | $1.90M 10-Q · filed 2019-11-14 | $3.80M derived: sum of 2 quarters · filed 2019-11-14 | |
| 2018-06-30 | $1.90M 10-Q · filed 2019-08-08 | ||
| 2017-12-31 | $0.00 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |